Whitepaper: Profiling oncology candidates
Posted: 9 February 2021 | Eurofins Discovery | No comments yet
Profiling oncology drug candidates through complementary in vitro assays and in vivo models to better understand their potential clinical applications.
In this whitepaper, we describe a profiling strategy that includes both in vitro and in vivo approaches to characterise sorafenib, an ATP-competitive multi-kinase inhibitor with clinical applications in multiple cancer types. Data for vemurafenib, an anti-neoplastic B-Raf kinase inhibitor, is also included to highlight how profiling compounds can shed light onto potentially different applications in the clinic.
Related content from this organisation
- Innovating Obesity Drug Discovery: Trends, Challenges, and Translational Strategies
- Early De-Risking: In Vitro Safety Strategies for Pre-IND Success
- Advancing ADC Development: End-to-End Solutions from Design to Characterization
- The future of carcinogenicity risk assessment: AI-powered, ethical alternatives to traditional testing
- Unprecedented fragment-based screening using Spectral Shift for GPCRs
Related topics
Assays, Biopharmaceuticals, Disease Research, Hit-to-Lead, In Vitro, In Vivo, Screening, Targets
Related organisations
Eurofins Discovery
